AU2006285349A1 - Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds - Google Patents

Description

WO 2007/027273 PCT/US2006/023695 5 Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds 10 FIELD OF INVENTION The present invention relates to compositions that are useful for the prevention and treatment of schizophrenia and similar psychiatric disorders. In particular, the present invention relates to compositions comprising an aryl-heterocyclic pharmaceutical compound, for example, ziprasidone. In one aspect of the invention, the composition is in 15 nanoparticulate form and comprises also at least one surface stabilizer. In another aspect, The present invention relates also to novel dosage forms for the controlled delivery of an aryl-heterocyclic pharmaceutical compound, for example, ziprasidone and to methods for the prevention and treatment of schizophrenia and similar psychiatric disorders. 20 BACKGROUND OF THE INVENTION Ziprasidone, chemically known as 5-[2-[4-(1,2-benzisothiazol-3-yl)- 1-piper azinyl]ethyl]-6-chloro- 1,3-dihydro-2H-indol-2-one, is a benzothiazolylpiperazine derivative that is used as an antipsychotic agent to treat psychiatric conditions such as 25 schizophrenia, hallucinations, delusions, hostility and other bipolar disorder without increase of lipids and other blood fats. Ziprasidone has an empirical formula of

C

21

H

21 C1N 4 0S and molecular weight of 412.94 (free base). The chemical structure of ziprasidone is shown below: WO 2007/027273 PCT/US2006/023695 C H NEN, Ziprasidone may be administered as part of a dosage form offered under the registered trademark name Geodone in the United States by Pfizer Inc. Ziprasidone is 5 present in Geodon* Capsules in the form of the hydrochloride salt of ziprasidone, 5-(2-(4 (1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one monohydrochloride monohydrate. This salt is a white to slightly pink powder, having a melting point of 300 'C, an empirical formula of C 21

H

21 ClN 4 OS-HCl-H 2 O and molecular weight of 467.42. Geodon* Capsules are supplied for oral administration in 20 mg, 40 10 mg, 60 mg and 80 mg capsules. Inactive ingredients within the Geodon* Capsules include lactose, pre-gelatinized starch and magnesium stearate. General dosing for patients includes oral dosage forms (capsules) for treating schizophrenia in adults dosed at 20 milligrams (mg) twice a day with food. Higher dosages may include dosages of 80 mg twice a day. 15 Ziprasidone is available for intramuscular injection in the form of ziprasidone mesylate under the trade name Geodon* for Injection. Geodon* for Injection contains a lyophilized form of ziprasidone mesylate trihydrate (5-(2-(4-(1,2-benzisothiazol-3 yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one, methanesulfonate, trihydrate 20 (empirical formula: C 2 1

H

21

CIN

4

OS-CH

3

SO

3 H-3H 2 O; molecular weight: 563.09). Geodon* for Injection is available in a single does vial as ziprasidone mesylate containing 20 mg ziprasidone/mL. Ziprasidone has been approved by the U.S. Food & Drug Administration (FDA) for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. 25 -2- WO 2007/027273 PCT/US2006/023695 The elimination half-life of ziprasidone is about 7 hours. Steady state plasma concentrations are achieved within one to three days. The bioavailability of ziprasidone is about 60% when taken with food. It has been reported that about one in twenty patients titrated up to high doses of Geodon* (360 mg a day) show a significant improvement in 5 cognition. Ziprasidone compounds have been described in U.S. Pat. Nos. 4,831,031; 6,110,918; 6,245,765; 6,150,366; 6,232,304; 6,399,777; and 6,245,766. United States Patent Pub. Nos. 2004/0138237 and 2004/0146562 disclose injectable depot formulations 10 of ziprasidone wherein the active ziprasidone compound is solubilized with a cyclodextrin to form a suspension. Ziprasidone is highly effective in the therapeutic treatment of patients suffering from schizophrenia and similar mental disorders. However, given the need to take 15 ziprasidone two times a day and the further need to take ziprasidone after meals, strict patient compliance is a critical factor in the efficacy of ziprasidone in the treatment of schizophrenia and similar mental disorders. Moreover, such frequent administration often requires the attention of health care workers and contributes to the high cost associated with treatments involving ziprasidone. Thus, there is a need in the art for ziprasidone 20 compositions which overcome these and other problems associated with their use in the treatment of schizophrenia and similar psychoses. Additionally, ziprasidone is practically insoluble in water. This poor water solubility results in poor bioavailability. 25 -3- WO 2007/027273 PCT/US2006/023695 SUMMARY OF THE INVENTION One embodiment of the invention encompasses a nanoparticulate composition comprising: (A) ziprasidone; and (B) at least one surface stabilizer. The surface stabilizer can be adsorbed on or associated with the surface of the nanoparticulate particles. The 5 nanoparticulate particles have an effective average particle size of less than about 2,000 nm. The nanoparticulate composition may optionally comprise one or more additional active ingredients useful in the prevention and treatment of schizophrenia and similar psychiatric disorders and/or one or more pharmaceutically acceptable excipients. In such embodiments, the administration of the nanoparticulate composition to a subject in a fed 10 or fasted state may be bioequivalent and may exhibit similar pharmacokinetics. The present invention also relates to modified release composition having a first component comprising a first population of active ingredient-containing particles and at least a second component comprising a second population of active ingredient-containing 15 particles, wherein each component has a different rate and/or duration of release and wherein at least one of said components comprises ziprasidone. The particles of the at least second component are provided in a modified release (MR) form such as, for example, coated with a modified release coating or comprising or incorporated in a modified release matrix material. Upon oral administration to a patient, the composition 20 releases the one or more active ingredients in a bimodal or multimodal manner. Such modified release compositions may comprise a nanoparticulate form of ziprasidone and at least one surface stabilizer, and may optionally comprise one or more additional active ingredients useful in the prevention and treatment of schizophrenia and similar psychiatric disorders and/or one or more pharmaceutically acceptable excipients. 25 The first component of the modified release composition may exhibit a variety of release profiles including profiles in which substantially all of the active ingredient contained in the first component is released rapidly upon administration of the dosage form, released rapidly but after a time delay (delayed release), or released slowly over 30 time. In one embodiment, the active ingredient contained in the first component of the dosage form is released rapidly upon administration to a patient. As used herein, -4- WO 2007/027273 PCT/US2006/023695 "released rapidly" includes release profiles in which at least about 80% of the active ingredient of a component of the dosage form is released within about an hour after administration, the term "delayed release" includes release profiles in which the active ingredient of a component of the dosage form is released (rapidly or slowly) after a time 5 delay, and the terms "controlled release" and "extended release" include release profiles in which at least about 80% of the active ingredient contained in a component of the dosage form is released slowly. The second component of the modified release composition may also exhibit a 10 variety of release profiles including an immediate release profile, a delayed release profile or a controlled release profile. In one embodiment, the second component exhibits a delayed release profile in which the active ingredient of the component is released after a time delay. In another embodiment, the second component exhibits a controlled release profile in which the active ingredient of the component is released over a period of about 15 12 to about 24 hours after administration. In two-component embodiments in which the components exhibit different release profiles, the release profile of the active ingredients from the composition is bimodal. In embodiments in which the first component exhibits an immediate release profile and the 20 second component exhibits a delayed release profile, there is a lag time between the release of active ingredient from the first component and the release of the active ingredient from the second component. The duration of the lag time may be varied by altering the amount and/or composition of the modified release coating or by altering the amount and/or composition of the modified release matrix material utilized to achieve the 25 desired release profile. Thus, the duration of the lag time can be designed to mimic a desired plasma profile. In embodiments in which the first component exhibits an immediate release profile and the second component exhibits a controlled release profile, the active 30 ingredients in the first and second components are released over different time periods. In such embodiments, the immediate release component serves to hasten the onset of -5- WO 2007/027273 PCT/US2006/023695 action by minimizing the time from administration to a therapeutically effective plasma concentration level, and the one or more subsequent components serve to minimize the variation in plasma concentration levels and/or maintain a therapeutically effective plasma concentration throughout the dosing interval. In one such embodiment, the active 5 ingredient in the first component is released rapidly and the active ingredient in the second component is released within a period of about 12 hours after administration. In another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released within a period of about 24 hours after administration. In yet another such embodiment, the active ingredient in the 10 first component is released rapidly and the active ingredient in the second component is released over a period of about 12 hours after administration. In still another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of about 24 hours after administration. In yet another such embodiment, the active ingredient in the first 15 component is released rapidly and the active ingredient in the second component is released over a period of at least about 12 hours after administration. In still another such embodiment, the active ingredient in the first component is released rapidly and the active ingredient in the second component is released over a period of at least about 24 hours after administration. 20 The plasma profile produced by the administration of dosage forms of the present invention which comprise an immediate release component and at least one modified release component can be substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially, or to the plasma 25 profile produced by the administration of separate IR and MR dosage forms. The modified release composition of the present invention is particularly useful for administering ziprasidone which is normally administered two times daily. In one embodiment of the present invention, the composition delivers the ziprasidone in a bimodal manner. Upon administration, such a composition produces a plasma profile 30 which substantially mimics that obtained by the sequential administration of two IR doses of ziprasidone in accordance with a typical treatment regimen. -6- WO 2007/027273 PCT/US2006/023695 According to another aspect of the present invention, the composition can be designed to produce a plasma profile that minimizes or eliminates the variations in plasma concentration levels associated with the administration of two or more IR dosage 5 forms given sequentially. In such embodiments, the composition may be provided with an immediate release component to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and at least one modified release component to maintain a therapeutically effective plasma concentration level throughout the dosing interval. The ziprasidone may be contained in 10 nanoparticulate particles which comprise also at least one surface stabilizer. Modified release compositions similar to those disclosed herein are disclosed and claimed in the United States Patent Nos. 6,228,398 and 6,730,325 to Devane et al. 15 The present invention also relates to dosage forms made from the compositions of the present invention. In one embodiment, the dosage form is a solid oral dosage form comprising the modified release composition of the present invention. The oral dosage form may utilize, for example, erodable formulations, diffusion controlled formulations and osmotic controlled formulations. In such embodiments, the total dose contained in 20 the dosage form may be release in a pulsatile or continuous manner. In one such embodiment, a portion of the total dose is released immediately to allow for rapid onset of effect, and the remainder of the total dose is release after a lag time or over a period of time up to about 24 hours. 25 In another embodiment, the dosage form is an injectable depot formulation comprising a nanoparticulate composition comprising ziprasidone. The depot formulation slowly dissolves and releases the drug into the patient's circulation. A single injection of the formulation can provide effective therapeutic plasma concentrations of ziprasidone for up to 3 months. 30 -7- WO 2007/027273 PCT/US2006/023695 The present invention is also directed to a method of making a nanoparticulate composition comprising ziprasidone. Such method comprises the step of contacting nanoparticulate particles comprising ziprasidone with at least one surface stabilizer for a period of time and under conditions sufficient to provide a stabilized nanoparticulate 5 composition comprising ziprasidone. The present invention further relates to methods of treatment including but not limited to, the prevention and treatment of schizophrenia and similar mental disorders. Such methods comprise the step of administering to a subject a therapeutically effective 10 amount of a composition, for example, a nanoparticulate composition, comprising ziprasidone. The compositions and dosage fors of the present invention are useful in reducing the required dosing frequency thereby increasing patient convenience and improving 15 patient compliance and, therefore, the therapeutic outcome for all treatments requiring ziprasidone including but not limited to, the prevention and treatment of schizophrenia and similar psychiatric disorders. This approach can replace conventional ziprasidone dosage forms, which are administered multiple times daily. 20 Both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention. 25 DETAILED DESCRIPTION OF THE INVENTION The present invention is described herein using several definitions as set forth below and throughout the application. 30 As used herein, "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. If there are uses of the -8- WO 2007/027273 PCT/US2006/023695 term which are not clear to persons of ordinary skill in the art given the context in which it is used, "about" will mean up to plus or minus 10% of the particular term. As used herein, "ziprasidone" includes ziprasidone, its pharmaceutically 5 acceptable salts, acids, esters, metabolites, complexes or other derivatives and thereof, and each of their respective stereoisomers including mixtures, racemic or otherwise, of two or more such stereoisomers. As used herein, "therapeutically effective amount of ziprasidone" means the 10 dosage that provides the specific pharmacological response for which the ziprasidone is administered in a significant number of subjects in need of the relevant treatment. It is emphasized that a therapeutically effective amount of ziprasidone that is administered to a particular subject in a particular instance will not always be effective in treating the conditions described herein, even though such dosage is deemed to be a therapeutically 15 effective amount by those of skill in the art. As used herein, "particulate" refers to a state of matter which is characterized by the presence of discrete particles, pellets, beads or granules irrespective of their size, shape or morphology. 20 As used herein, "multiparticulate" means a plurality of discrete, or aggregated, particles, pellets, beads, granules or mixture thereof irrespective of their size, shape or morphology. A composition comprising a multiparticulate is described herein as a "multiparticulate composition." 25 As used herein, "nanoparticulate" refers to a multiparticulate in which the effective average particle size of the particles therein is less than about 2000 nm (2 microns) in diameter. A composition comprising a nanoparticulate is described herein as a "nanoparticulate composition." 30 -9-- WO 2007/027273 PCT/US2006/023695 As used herein, "effective average particle size" to describe a multiparticulate (e.g., a nanoparticulate) means that at least 50% of the particles thereof are of a specified size. Accordingly, "effective average particle size of less than about 2000 nm in diameter" means that at least 50% of the particles therein are less than about 2000 nm in 5 diameter. As used herein, "D50" refers to the particle size below which 50% of the particles in a multiparticulate fall. Similarly, "D90" refers to the particle size below which 90% of the particles in a multiparticulate fall. 10 As used herein with reference to stable particles, "stable" refers to, but is not limited to, one or more of the following parameters: (1) the particles do not appreciably flocculate or agglomerate due to interparticle attractive forces or otherwise significantly increase in particle size over time; (2) the physical structure of the particles is not altered 15 over time, such as by conversion from an amorphous phase to a crystalline phase; (3) the particles are chemically stable; and/or (4) where the active ingredient has not been subject to a heating step at or above the melting point of the particles in the preparation of the nanoparticles of the present invention. 20 As used herein, "poorly water soluble drug" refers to a drug that has a solubility in water of less than about 30 mg/ml, less than about 20 mg/ml, less than about 10 mg/ml, or less than about 1 mg/ml. As used herein, "modified release" includes a release which is not immediate and 25 includes controlled release, extended release, sustained release and delayed release. As used herein, "time delay" refers to the period of time between the administration of a dosage form comprising the composition of the invention and the release of the active ingredient from a particular component thereof. 30 - 10 - WO 2007/027273 PCT/US2006/023695 As used herein, "lag time" refers to the time between the release of the active ingredient from one component of the composition and the release of the active ingredient from another component of the composition. 5 As used herein, "erodable" refers to formulations which may be worn away, diminished, or deteriorated by the action of substances within the body. As used herein, "diffusion controlled" refers to formulations which may spread as the result of their spontaneous movement, for example, from a region of higher to one of 10 lower concentration. As used herein, "osmotic controlled" refers to formulations which may spread as the result of their movement through a semi-permeable membrane into a solution of higher concentration that tends to equalize the concentrations of the formulation on the 15 two sides of the membrane. 1. Nanoparticulate Compositions Comprising Ziprasidone The present invention provides a nanoparticulate composition comprising particles which comprise: (A) ziprasidone, or a salt or derivative thereof; and (B) at least one 20 surface stabilizer. Nanoparticulate compositions were first described in U.S. Patent No. 5,145,684. Nanoparticulate active agent compositions are described also in, for example, U.S. Patent Nos. 5,298,262; 5,302,401; 5,318,767; 5,326,552; 5,328,404; 5,336,507; 5,340,564; 5,346,702; 5,349,957; 5,352,459; 5,399,363; 5,494,683; 5,401,492; 5,429,824; 5,447,710; 5,451,393; 5,466,440; 5,470,583; 5,472,683; 5,500,204; 5,518,738; 5,521,218; 25 5,525,328; 5,543,133; 5,552,160; 5,565,188; 5,569,448; 5,571,536; 5,573,749; 5,573,750; 5,573,783; 5,580,579; 5,585,108; 5,587,143; 5,591,456; 5,593,657; 5,622,938; 5,628,981; 5,643,552; 5,718,388; 5,718,919; 5,747,001; 5,834,025; 6,045,829; 6,068,858; 6,153,225; 6,165,506; 6,221,400; 6,264,922; 6,267,989; 6,270,806; 6,316,029; 6,375,986; 6,428,814; 6,431,478; 6,432,381; 6,582,285; 6,592,903; 6,656,504; 6,742,734; 6,745,962; 6,811,767; 30 6,908,626; 6,969,529; 6,976,647; and 6,991,191; and U.S. Patent Publication Nos. 20020012675;20050276974;20050238725;20050233001;20050147664;20050063913; - 11- WO 2007/027273 PCT/US2006/023695 20050042177;20050031691;20050019412;20050004049;20040258758;20040258757; 20040229038;20040208833;20040195413;20040156895;20040156872;20040141925; 20040115134;20040105889;20040105778;20040101566;20040057905;20040033267; 20040033202;20040018242;20040015134;20030232796;20030215502;20030185869; 5 20030181411;20030137067;20030108616;20030095928;20030087308;20030023203; 20020179758; 20020012675; and 20010053664. Amorphous small particle compositions are described, for example, in U.S. Patent Nos. 4,783,484; 4,826,689; 4,997,454; 5,741,522; 5,776,496. 10 As stated above, the effective average particle size of the particles in the nanoparticulate composition of the present invention is less than about 2000 nm (i.e., 2 microns) in diameter. In embodiments of the present invention, the effective average particle size may be, for example, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 15 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 rim, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 mu, less than about 250 mu, less than about 200 nm, less than about 150 nm, less than about 100 nim, less than about 75 nm, or less than about 50 nm in diameter, 20 as measured by light-scattering methods, microscopy, or other appropriate methods. The nanoparticulate particles may exist in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi amorphous phase, or a mixture thereof. 25 In addition to allowing for a smaller solid dosage form size, the nanoparticulate composition of the present invention exhibits increased bioavailability, and requires smaller doses of the ziprasidone as compared to prior conventional, non-nanoparticulate compositions which comprise ziprasidone. In one embodiment of the invention, the nanoparticulate composition of the present invention has a bioavailability that is about 30 50% greater than ziprasidone administered in a conventional dosage form. In other embodiments, the nanoparticulate composition of the present invention has a - 12 - WO 2007/027273 PCT/US2006/023695 bioavailability that is about 40% greater, about 30% greater, about 20% or about 10% greater than ziprasidone administered in a conventional dosage form. The nanoparticulate composition may also have a desirable pharmacokinetic 5 profile as measured following the initial dosage thereof to a mammalian subject. The desirable pharmacokinetic profile of the composition includes, but is not limited to: (1) a Cmax for ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably greater than the Cmax for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition; and/or (2) an AUC for 10 ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably greater than the AUC for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition; and/or (3) a Tmax for ziprasidone when assayed in the plasma of a mammalian subject following administration that is preferably less than the Tma for the same ziprasidone delivered at the same dosage by a non 15 nanoparticulate composition. In an embodiment of the present invention, a nanoparticulate composition of the present invention exhibits, for example, a Tmax for ziprasidone contained therein which is not greater than about 90% of the Tmax for the same ziprasidone delivered at the same 20 dosage by a non-nanoparticulate composition. In other embodiments of the present invention, the nanoparticulate composition of the present invention may exhibit, for example, a Tmax for ziprasidone contained therein which is not greater than about 80%, not greater than about 70%, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not 25 greater than about 15%, not greater than about 10%, or not greater than about 5% of the Tmax for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition. In one embodiment of the invention, the Tmax of ziprasidone when assayed in the plasma of the mammalian subject is less than about 6 to about 8 hours after administration. In other embodiments of the invention, the Tmax of 30 ziprasidone is less than about 6 hours, less than about 5 hours, less than about 4 - 13 - WO 2007/027273 PCT/US2006/023695 hours, less than about 3 hours, less than about 2 hours, less than about I hour, or less than about 30 minutes after administration. In an embodiment of the present invention, a nanoparticulate composition of the 5 present invention exhibits, for example, a Cmnax for ziprasidone contained therein which is at least about 50% of the Cmax for the same ziprasidone delivered at the same dosage by a non-nanoparticulate composition. In other embodiments of the present invention, the nanoparticulate composition of the present invention may exhibit, for example, a Cmax for ziprasidone contained therein which is at least about 100%, at least about 200%, at least 10 about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700%, at least about 800%, at least about 900%, at least about 1000%, at least about 1100%, at least about 1200%, at least about 1300%, at least about 1400%, at least about 1500%, at least about 1600%, at least about 1700%, at least about 1800%, or at least about 1900% greater than the Cmax for the same ziprasidone delivered at the same dosage 15 by a non-nanoparticulate composition. In an embodiment of the present invention, a nanoparticulate composition of the present invention exhibits, for example, an AUC for ziprasidone contained therein which is at least about 25% greater than the AUC for the same ziprasidone delivered at the same 20 dosage by a non-nanoparticulate composition. In other embodiments of the present invention, the nanoparticulate composition of the present invention may exhibit, for example, an AUC for ziprasidone contained therein which is at least about 50%, at least about 75%, at least about 100%, at least about 125%, at least about 150%, at least about 175%, at least about 200%, at least about 225%, at least about 250%, at least about 275%, 25 at least about 300%, at least about 350%, at least about 400%, at least about 450%, at least about 500%, at least about 550%, at least about 600%, at least about 750%, at least about 700%, at least about 750%, at least about 800%, at least about 850%, at least about 900%, at least about 950%, at least about 1000%, at least about 1050%, at least about 1100%, at least about 1150%, or at least about 1200% greater than the AUC for the same 30 ziprasidone delivered at the same dosage by a non-nanoparticulate composition. - 14 - WO 2007/027273 PCT/US2006/023695 The invention encompasses a nanoparticulate composition wherein the pharmacokinetic profile of ziprasidone following administration is not substantially affected by the fed or fasted state of a subject ingesting the composition. This means that there is no substantial difference in the quantity of ziprasidone absorbed or the rate of 5 absorption when the nanoparticulate composition is administered in the fed versus the fasted state. In conventional ziprasidone formulations, i.e., Geodon*, the absorption of ziprasidone is increased when administered with food. This difference in absorption observed with conventional ziprasidone formulations is undesirable. The composition of the invention overcomes this problem. 10 Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant as, with poor subject compliance, an increase in the medical condition for 15 which the ziprasidone is being prescribed may be observed. The invention encompasses also a nanoparticulate composition comprising ziprasidone in which administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state. 20 The difference in absorption of the composition of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than bout 95%, less than about 90%, less than about 85%, less than about 80%, less than about 75%, less than about 70%, less than about 65%, less than about 60%, less than 25 about 55%, less than about 50%, less than about 45%, less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, or less than about 3%. In one embodiment of the invention, the invention encompasses a composition 30 comprising ziprasidone wherein the administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed - 15 - WO 2007/027273 PCT/US2006/023695 state, in particular as defined by Cmnax and AUC guidelines given by the U.S. Food and Drug Administration and the corresponding European regulatory agency (EMEA). Under U.S. FDA guidelines, two products or methods are bioequivalent if the 90% Confidence Intervals (CI) for AUC and Gmax are between 0.80 to 1.25 (T,,ax measurements are not 5 relevant to bioequivalence for regulatory purposes). To show bioequivalency between two compounds or administration conditions pursuant to Europe's EMEA guidelines, the 90% CI for AUC must be between 0.80 to 1.25 and the 90% CI for Cmax must between 0.70 to 1.43. 10 The nanoparticulate composition of the invention is proposed to have an unexpectedly dramatic dissolution profile. Rapid dissolution of ziprasidone is preferable, as faster dissolution generally leads to faster onset of action and greater bioavailability. To improve the dissolution profile and bioavailability of the ziprasidone, it would be useful to increase the drug's dissolution so that it could attain a level close to 100%. 15 The compositions of the invention preferably have a dissolution profile in which within about 5 minutes at least about 20% of the ziprasidone is dissolved. In other embodiments of the invention, at least about 30% or at least about 40% of the ziprasidone is dissolved within about 5 minutes. In yet other embodiments of the invention, 20 preferably at least about 40%, at least about 50%, at least about 60%, at least about 70%, or at least about 80% of the ziprasidone is dissolved within about 10 minutes. Finally, in another embodiment of the invention, preferably at least about 70%, at least about 80%, at least about 90%, or at least about 100% of the ziprasidone is dissolved within about 20 minutes. 25 Dissolution is preferably measured in a medium which is discriminating. Such a dissolution medium will produce two very different dissolution curves for two products having very different dissolution profiles in gastric juices; i.e., the dissolution medium is predictive of in vivo dissolution of a composition. An exemplary dissolution medium is 30 an aqueous medium containing the surfactant sodium lauryl sulfate at 0.025 M. - 16 - WO 2007/027273 PCT/US2006/023695 Determination of the amount dissolved can be carried out by spectrophotometry. The rotating blade method (European Pharmacopoeia) can be used to measure dissolution. An additional feature of the nanoparticulate composition of the invention is that 5 particles thereof redisperse so that the particles have an effective average particle size of less than about 2000 rn in diameter. This is significant because, if the particles did not redisperse so that they have an effective average particle size of less than about 2000 nm in diameter, the composition may lose the benefits afforded by formulating the ziprasidone therein into a nanoparticulate fonn. This is because nanoparticulate 10 compositions benefit from the small size of the particles comprising the ziprasidone. If the particles do not redisperse into small particle sizes upon administration, then "clumps" or agglomerated particles are formed, owing to the extremely high surface free energy of the nanoparticulate system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the 15 bioavailability of the dosage form may fall well below that observed with the liquid dispersion form of the nanoparticulate composition. In other embodiments of the invention, the redispersed particles of the invention (redispersed in water, a biorelevant media, or any other suitable liquid media) have an 20 effective average particle size of less than about less than about 1900 n, less than about 1800 n, less than about 1700 un, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 rn, less than about 1200 nm, less than about 1100 nn, less than about 1000 rn, less than about 900 rn, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 un, less than about 25 400 n, less than about 300 un, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 um in diameter, as measured by light-scattering methods, microscopy, or other appropriate methods. Such methods suitable for measuring effective average particle size are known to a person of ordinary skill in the art. 30 - 17 - WO 2007/027273 PCT/US2006/023695 Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate." 5 The nanoparticulate composition of the present invention exhibits dramatic redispersion of the particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution/redispersion in a biorelevant aqueous media, such that the effective average particle size of the redispersed particles is less than about 10 2000 rn. Such biorelevant aqueous media can be any aqueous media that exhibits the desired ionic strength and pH, which form the basis for the biorelevance of the media. The desired pH and ionic strength are those that are representative of physiological conditions found in the human body. Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a 15 combination thereof, which exhibit the desired pH and ionic strength. Biorelevant pH is well known in the art. For example, in the stomach, the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5. In the small intestine the pH can range from 4 to 6, and in the colon it can range from 6 to 8. 20 Biorelevant ionic strength is also well known in the art. Fasted state gastric fluid has an ionic strength of about 0. 1M while fasted state intestinal fluid has an ionic strength of about 0.14. See e.g., Lindahl et al., "Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women," Pharm. Res., 14 (4): 497-502 (1997). It is believed that the pH and ionic strength of the test solution is more critical than the 25 specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc. 30 Representative electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 N, and NaCl solutions, ranging in - 18 - WO 2007/027273 PCT/US2006/023695 concentration from about 0.001 to about 0.1 M, and mixtures thereof. For example, electrolyte solutions can be, but are not limited to, about 0.1 N HCI or less, about 0.01 N HCl or less, about 0.001 N HCl or less, about 0.1 M NaCI or less, about 0.01 M NaCL or less, about 0.001 M NaCI or less, and mixtures thereof. Of these electrolyte solutions, 5 0.01 M HCl and/or 0.1 M NaCl, are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract. Electrolyte concentrations of 0.001 N HCL, 0.01 N HCl, and 0.1 N HCl correspond 10 to pH 3, pH 2, and pH 1, respectively. Thus, a 0.01 N HCI solution simulates typical acidic conditions found in the stomach. A solution of 0.1 M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0.1 M may be employed to simulate fed conditions within the human GI tract. 15 Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength, include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic 20 acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride. As stated above, the composition comprises also at least one surface stabilizer. The surface stabilizer can be adsorbed on or associated with the surface of the 25 ziprasidone-containing particles. Preferably, the surface stabilizer adheres on, or associates with, the surface of the particles, but does not react chemically with the particles or with other surface stabilizer molecules. Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular cross-linkages. 30 The relative amounts of the ziprasidone and surface stabilizer present in the composition of the present invention can vary widely. The optional amount of the - 19 - WO 2007/027273 PCT/US2006/023695 individual components can depend, upon, among other things, the particular drug selected, the hydrophilic-lipophilic balance (HLB), melting point, and the surface tension of water solutions of the stabilizer. The concentration of the ziprasidone can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to 5 about 0.5%, by weight, based on the total combined weight of the ziprasidone and surface stabilizer(s), not including other excipients. The concentration of the surface stabilizer(s) can vary from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5%, by weight, based on the total combined dry weight of the ziprasidone, or a salt or derivative thereof, and surface stabilizer(s), not including other 10 excipients. The choice of a surface stabilizer(s) for the ziprasidone is non-trivial and required extensive experimentation to realize a desirable formulation. Accordingly, the present invention is directed to the surprising discovery that nanoparticulate compositions 15 comprising ziprasidone can be made. Combinations of more than one surface stabilizer can be used in the invention. Useful surface stabilizers which can be employed in the invention include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients 20 include various polymers, low molecular weight oligomers, natural products, and surfactants. Surface stabilizers include nonionic, anionic, cationic, ionic, and zwitterionic surfactants. Representative examples of surface stabilizers include hydroxypropyl 25 methylcellulose (now known as hypromellose), hydroxypropyleellulose, polyvinylpyrrolidone, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., 30 macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens* such -20- WO 2007/027273 PCT/US2006/023695 as e.g., Tween 20* and Tween 80* (ICI Speciality Chemicals)); polyethylene glycols (e.g., Carbowaxs 3550* and 934* (Union Carbide)), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline 5 cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), 4 (1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68* and F108, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908*, also known as Poloxamine 908*, which is a tetrafunctional block 10 copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); Tetronic 1508* (T 1508) (BASF Wyandotte Corporation), Tritons X-200*, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-1 10*, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin 15 OG* or Surfactant 10-G* (Olin Chemicals, Stamford, CT); Crodestas SL-40*(Croda, Inc.); and SA90HCO, which is C1 8H37CH2(CON(CH3)-CH2(CHOH)4(CH20H)2 (Eastman Kodak Co.); decanoyl-N-methylglucamide; n-decyl p-D-glucopyranoside; n decyl p-D-maltopyranoside; n-dodecyl -D-glucopyranoside; n-dodecyl P-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-p-D-glucopyranoside; n-heptyl p-D 20 thioglucoside; n-hexyl p--D-glucopyranoside; nonanoyl-N-methylglucamide; n-noyl p-D glucopyranoside; octanoyl-N-methylglucamide; n-octyl-p-D-glucopyranoside; octyl P-D thioglucopyranoside; PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, and the like. 25 Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, 30 polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide -21- WO 2007/027273 PCT/US2006/023695 bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate. Other useful cationic stabilizers include, but are not limited to, cationic lipids, 5 sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C 1 2 -isdimethyl hydroxyethyl ammonium 10 chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N-alkyl

(C

1 2

..

1 8)dimethylbenzyl ammonium chloride, N-alkyl (C 1 4 -1 8 )dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl 15 ammonium chloride, N-alkyl and (C 1 2

-

1 4 ) dimethyl 1-napthylmethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts and dialkyl dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N-didecyldimethyl ammonium chloride, N 20 tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C 1 2

-

1 4 ) dimethyl 1 naphthylnethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C 1 2 ,

C

15 , C 1 7 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, 25 poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT 3 3 6TM), POLYQUAT 1OTM, tetrabutylammonium bromide, benzyl trimethylammonium 30 bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di - 22 - WO 2007/027273 PCT/US2006/023695 stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quatemized polyoxyethylalkylamines, MIRAPOLTM and ALKAQUATTM (Alkaril Chemical Company), alkyl pyridinium salts; aminies, such as alkylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl 5 pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[diallyl dimethylammonium chloride] and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar. 10 Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chiemistiy (Marcel Dekker, 1991); and J. Richmond, Cationic 15 Suifactants: Organic Chenisty, (Marcel Dekker, 1990). Nonpolymeric surface stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary 20 phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NRR 2

R

3 R(+). For compounds of the formula

NR

1

R

2

R

3 R'+): 25 (i) none of R-R 4 are CH 3 ; (ii) one of R,-R4 is CH 3 ; (iii) three of RI-R4 are CH 3 ; (iv) all of R -R 4 are CH 3 ; (v) two of R 1

-R

4 are CH 3 , one of Rr-R 4 is C 6

H

5

CH

2 , and one of R-R 4 is an 30 alkyl chain of seven carbon atoms or less; - 23 - WO 2007/027273 PCT/US2006/023695 (vi) two of RI-R 4 are CH 3 , one of R-R 4 is C 6

H

5

CH

2 , and one of R-R 4 is an alkyl chain of nineteen carbon atoms or more; (vii) two of R-R 4 are CH 3 and one of R-R 4 is the group C 6 Hs(CH 2 )n, where n>1; 5 (viii) two of R 1

-R

4 are CH 3 , one of R 1 -R4 is C 6

H

5

CH

2 , and one of R,-R 4 comprises at least one heteroatom; (ix) two of R-R 4 are CH 3 , one of R 1

-R

4 is C 6

HSCH

2 , and one of R-R4 comprises at least one halogen; (x) two of R-R 4 are CH 3 , one of RI-R 4 is C 6

H

5

CH

2 , and one of Rj-R 4 10 comprises at least one cyclic fragment; (xi) two of R, -R 4 are CH 3 and one of R, -R 4 is a phenyl ring; or (xii) two of R, -R 4 are CH 3 and two of R -R 4 are purely aliphatic fragments. Such compounds include, but are not limited to, behenalkonium chloride, 15 benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium 14), Quaternium-22, Quaternium-26, Quaternium- 18 hectorite, dimethylaminoethyl 20 chloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCI, iofetamine 25 hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquaternium-1, procainehydrochloride, cocobetaine, stearalkonium bentonite, stearalkoniumhectonite, stearyl trihydroxyethyl propylenediamine dihydrofluoride, tallowtrimonium chloride, and hexadecyltrimethyl ammonium bromide. 30 -24 - WO 2007/027273 PCT/US2006/023695 The surface stabilizers are commercially available and/or can be prepared by techniques known in the art. Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook ofPharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical 5 Society of Great Britain (The Pharmaceutical Press, 2000). The compositions of the invention can comprise, in addition to ziprasidone, one or more compounds useful in treating schizophrenia or similar mental disorders and related conditions. The composition may also be administered in conjunction with such a 10 compound. These other active compounds preferably include those useful for treatment of bodily conditions such as headaches, fevers, soreness, and other like conditions that are generally occasioned with schizophrenia and similar psychiatric disorders. Such active compounds should be present in a manner, as determined by one skilled in the art, such that they do not interfere with the therapeutic effect of ziprasidone. 15 The composition of the present invention may comprise also one or more binding agents, filling agents, diluents, lubricating agents, emulsifying and suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, perfuming agents, and other excipients. Such excipients are known 20 in the art. In addition, prevention of the growth of microorganisms can be ensured by the addition of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. For use in injectable formulations, the composition may comprise also isotonic agents, such as sugars, sodium chloride, and the like and agents for use in delaying the absorption of the injectable pharmaceutical form, such as aluminum 25 monostearate and gelatin. Examples of filling agents are lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel® PHIO and Avicel* 30 PHI 02, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM). -25- WO 2007/027273 PCT/US2006/023695 Suitable lubricants, including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil* 200, tale, stearic acid, magnesium stearate, calcium stearate, and silica gel. 5 Examples of sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acsulfame. Examples of flavoring agents are Magnasweet* (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like. 10 Examples of preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride. 15 Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystalline cellulose, such as Avicel* PH 101 and Avicel* PH 102; lactose such as lactose 20 monohydrate, lactose anhydrous, and Pharmatose* DCL21; dibasic calcium phosphate such as Emcompress*; mannitol; starch; sorbitol; sucrose; and glucose. Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross 25 povidone, sodium starch glycolate, and mixtures thereof. Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. 30 Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium -26- WO 2007/027273 PCT/US2006/023695 glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the sodium bicarbonate component of the effervescent couple may be present. The composition of the present invention may comprise also a carrier, adjuvant, or 5 a vehicle (hereafter, collectively, "carriers"). The nanoparticulate compositions can be made using, for example, milling, homogenization, precipitation, freezing, or template emulsion techniques. Exemplary methods of making nanoparticulate compositions are described in the '684 patent. 10 Methods of making nanoparticulate compositions are described also in U.S. Patent Nos. 5,518,187; 5,718,388; 5,862,999; 5,665,331; 5,662,883; 5,560,932; 5,543,133; 5,534,270; 5,510,118; and 5,470,583. In one method, particles comprising ziprasidone are dispersed in a liquid 15 dispersion medium in which the ziprasidone is poorly soluble. Mechanical means are then used in the presence of grinding media to reduce the particle size to the desired effective average particle size. The dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol. A preferred dispersion medium is water. The particles can be reduced in size in the 20 presence of at least one surface stabilizer. The particles comprising ziprasidone can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent-, can be added to the composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode. One skilled in the art would understand that it may be the case that, following milling, not all particles may be reduced 25 to the desired size. In such an event, the particles of the desired size may be separated and used in the practice of the present invention. Another method of forming the desired nanoparticulate composition is by microprecipitation. This is a method of preparing stable dispersions of poorly soluble 30 ziprasidone in the presence of surface stabilizer(s) and one or more colloid stability enhancing surface active agents free of any trace toxic solvents or solubilized heavy metal - 27 - WO 2007/027273 PCT/US2006/023695 impurities. Such a method comprises, for example: (1) dissolving ziprasidone in a suitable solvent; (2) adding the formulation from step (1) to a solution comprising at least one surface stabilizer; and (3) precipitating the formulation from step (2) using an appropriate non-solvent. The method can be followed by removal of any formed salt, if 5 present, by dialysis or diafiltration and concentration of the dispersion by conventional means. A nanoparticulate composition may be formed also by homogenization. Exemplary homogenization methods are described in U.S. Patent No. 5,510,118, for 10 "Process of Preparing Therapeutic Compositions Containing Nanoparticles." Such a method comprises dispersing particles comprising ziprasidone in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size to the desired effective average particle size. The particles can be reduced in size in the presence of at least one surface stabilizer. The particles can be contacted with one or 15 more surface stabilizers either before or after attrition. Other compounds, such as a diluent, can be added to the composition before, during, or after the size reduction process. Dispersions can be manufactured continuously or in a batch mode. Another method of forming the desired nanoparticulate composition is by spray 20 freezing into liquid (SFL). This technology comprises injecting an organic or organoaqueous solution of ziprasidone and surface stabilizer(s) into a cryogenic liquid, such as liquid nitrogen. The droplets of the drug-containing solution freeze at a rate sufficient to minimize crystallization and particle growth, thus formulating nano structured particles. Depending on the choice of solvent system and processing 25 conditions, the particles can have varying particle morphology. In the isolation step, the nitrogen and solvent are removed under conditions that avoid agglomeration or ripening of the particles. As a complementary technology to SFL, ultra rapid freezing (URF) may also be 30 used to create equivalent nanostructured particles with greatly enhanced surface area. - 28 - WO 2007/027273 PCT/US2006/023695 URF comprises taking a water-miscible, anhydrous, organic, or organoaqueous solution of ziprasidone and surface stabilizer(s) and applying it onto a cryogenic substrate. The solvent is then removed by means such as lyophilization or atmospheric freeze-drying with the resulting nanostructured particles remaining. 5 Another method of forming the desired nanoparticulate composition is by template emulsion. Template emulsion creates nano-structured particles with controlled particle size distribution and rapid dissolution performance. The method comprises preparing an oil-in-water emulsion and then swelling it with a non-aqueous solution 10 comprising ziprasidone and surface stabilizer(s). The size distribution of the particles is a direct result of the size of the emulsion droplets prior to loading of the emulsion with the drug. The particle size can be controlled and optimized in this process. Furthermore, through selected use of solvents and stabilizers, emulsion stability is achieved with no or suppressed Ostwald ripening. Subsequently, the solvent and water are removed, and the 15 stabilized nano-structured particles are recovered. Various particle morphologies can be achieved by appropriate control of processing conditions. The invention also provides a method comprising the administration of an effective amount of a nanoparticulate composition comprising ziprasidone. 20 The composition of the present invention can be formulated for administration parentally (e.g., intravenous, intramuscular, or subcutaneous), orally (e.g., in solid, liquid, or aerosol form, vaginal), nasally, rectally, ocularly, locally (e.g., in powder, ointment, or drop form), buccally, intracisternally, intraperitoneally, or topically, and the like. 25 The nanoparticulate composition can be utilized in solid or liquid dosage formulations, such as liquid dispersions, gels, aerosols, ointments, depots, creams, controlled release formulations, fast melt formulations, lyophilized formulations, tablets, capsules, delayed release formulations, extended release formulations, pulsatile release 30 formulations, mixed immediate release and controlled release formulations, etc. -29- WO 2007/027273 PCT/US2006/023695 Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents, 5 or vehicles including water, ethanol, polyols (propyleneglycol, polyethylene-glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. 10 Solid dosage forms for oral administration include, but are not limited to, tablets, capsules, sachets, lozenges, powders, pills, or granules, and the solid dosage form can be, for example, a fast melt dosage form, controlled release dosage form, lyophilized dosage form, delayed release dosage form, extended release dosage form, pulsatile release dosage 15 form, mixed immediate release and controlled release dosage form, or a combination thereof. A solid dose tablet formulation is preferred. In such solid dosage forms, the active agent is admixed with at least one of the following: (a) one or more inert excipients (or carriers), such as sodium citrate or dicalciurn phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) 20 binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl 25 alcohol and glycerol monostearate; (i) adsorbents, such as kaolin and bentonite; and () lubricants, such as tale, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. For capsules, tablets, and pills, the dosage forms may also comprise buffering agents. 30 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to ziprasidone, the -30 - WO 2007/027273 PCT/US2006/023695 liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as 5 cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like. One of ordinary skill will appreciate that a therapeutically effective amount of 10 ziprasidone can be determined empirically. Actual dosage levels of ziprasidone in the nanoparticulate compositions of the invention may be varied to obtain an amount of the drug that is effective to obtain a desired therapeutic response for a particular composition and method of administration. The selected dosage level therefore depends upon the desired therapeutic effect, the route of administration, the potency of the administered 15 ziprasidone the desired duration of treatment, and other factors. Dosage unit compositions may contain such amounts of ziprasidone or such submultiples thereof as may be used to make up the daily dose. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety 20 of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the ziprasidone; the duration of the treatment; active compound used in combination or coincidental with 25 ziprasidone; and like factors well known in the medical arts. II. Controlled Release Compositions Comprising Ziprasidone The effectiveness of pharmaceutical compounds in the prevention and treatment of disease states depends on a variety of factors including the rate and duration of 30 delivery of the compound from the dosage form to the patient. The combination of delivery rate and duration exhibited by a given dosage form in a patient can be described -31 - WO 2007/027273 PCT/US2006/023695 as its in vivo release profile and, depending on the pharmaceutical compound administered, will be associated with a concentration and duration of the pharmaceutical compound in the blood plasma, referred to as a plasma profile. As pharmaceutical compounds vary in their pharmacokinetic properties such as bioavailability, and rates of 5 absorption and elimination, the release profile and the resultant plasma profile become important elements to consider in designing effective therapies. The release profiles of dosage forms may exhibit different rates and durations of release and may be continuous or pulsatile. Continuous release profiles include release 10 profiles in which a quantity of one or more pharmaceutical compounds is released continuously throughout the dosing interval at either a constant or variable rate. Pulsatile release profiles include release profiles in which at least two discrete quantities of one or more pharmaceutical compounds are released at different rates and/or over different time frames. For any given pharmaceutical compound or combination of such compounds, the 15 release profile for a given dosage form gives rise to an associated plasma profile in a patient. When two or more components of a dosage form have different release profiles, the release profile of the dosage form as a whole is a combination of the individual release profiles and may be described generally as "multimodal." The release profile of a two-component dosage form in which each component has a different release profile may 20 described as "bimodal," and the release profile of a three-component dosage form in which each component has a different release profile may described as "trimodal." Similar to the variables applicable to the release profile, the associated plasma profile in a patient may exhibit constant or variable blood plasma concentration levels of 25 the pharmaceutical compounds over the duration of action and may be continuous or pulsatile. Continuous plasma profiles include plasma profiles of all rates and duration which exhibit a single plasma concentration maximum. Pulsatile plasma profiles include plasma profiles in which at least two higher blood plasma concentration levels of pharmaceutical compound are separated by a lower blood plasma concentration level and 30 may be described generally as "multimodal." Pulsatile plasma profiles exhibiting two peaks may be described as "bimodal" and plasma profiles exhibiting three peaks may be - 32 - WO 2007/027273 PCT/US2006/023695 described as "trimodal." Depending on, at least in part, the pharmacokinetics of the pharmaceutical compounds included in the dosage form as well as the release profiles of the individual components of the dosage form, a multimodal release profile may result in either a continuous or a pulsatile plasma profile upon administration to a patient. 5 In one embodiment, the present invention provides a multiparticulate modified release composition which delivers ziprasidone, or nanoparticles containing ziprasidone, in a pulsatile manner. The nanoparticles are of the type described above and comprise also at least one surface stabilizer. 10 In still another embodiment, the present invention provides a multiparticulate modified release composition which delivers ziprasidone, or nanoparticles containing ziprasidone, in a continuous manner. The nanoparticles are of the type described above and comprise also at least one surface stabilizer. 15 In yet another embodiment, the present invention provides a multiparticulate modified release composition in which a first portion of ziprasidone, or nanoparticles containing ziprasidone, is released immediately upon administration and one or more subsequent portions of ziprasidone, or nanoparticles containing ziprasidone, are released 20 after an initial time delay. In yet another embodiment, the present invention provides solid oral dosage forms for once-daily or twice-daily administration comprising the multiparticulate modified release composition of the present invention. 25 In still another embodiment, the present invention provides a method for the prevention and/or treatment of schizophrenia and similar psychiatric disorders comprising the administration of a composition of the present invention. 30 In an embodiment, the present invention provides a multiparticulate modified release composition in which the particles forming the multiparticulate are - 33 - WO 2007/027273 PCT/US2006/023695 nanoparticulate particles of the type described above. The nanoparticulate particles may, as desired, contain a modified release coating and/or a modified release matrix material. According to one aspect of the present invention, there is provided a 5 pharmaceutical composition having a first component comprising active ingredient containing particles, and at least one subsequent component comprising active ingredient containing particles, each subsequent component having a rate and/or duration of release different from the first component wherein at least one of said components comprises particles containing ziprasidone. In an embodiment of the invention, ziprasidone 10 containing particles that form the multiparticulate may themselves contain nanoparticulate particles of the type described above which comprise ziprasidone and also at least one surface stabilizer. In another embodiment of the invention, nanoparticulate particles of the type described above which comprise ziprasidone and also at least one surface stabilizer themselves are the drug-containing particles of the multiparticulate. 15 The drug-containing particles may be coated with a modified release coating. Alternatively or additionally, the drug-containing particles may comprise a modified release matrix material. Following oral delivery, the composition delivers ziprasidone, or nanoparticles containing ziprasidone, in a pulsatile manner. In one embodiment, the first component provides an immediate release of ziprasidone, or nanoparticles containing 20 ziprasidone, and the one or more subsequent components provide a modified release of ziprasidone, or nanoparticles containing ziprasidone. In such embodiments, the immediate release component serves to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and the one or more subsequent components serve to minimize the variation in plasma concentration 25 levels and/or maintain a therapeutically effective plasma concentration throughout the dosing interval. The modified release coating and/or the modified release matrix material cause a lag time between the release of the active ingredient from the first population of active 30 ingredient-containing particles and the release of the active ingredient from subsequent populations of active ingredient-containing particles. Where more than one population of - 34 - WO 2007/027273 PCT/US2006/023695 active ingredient-containing particles provide a modified release, the modified release coating and/or the modified release matrix material causes a lag time between the release of the active ingredient from the different populations of active ingredient-containing particles. The duration of these lag times may be varied by altering the composition 5 and/or the amount of the modified release coating and/or altering the composition and/or amount of modified release matrix material utilized. Thus, the duration of the lag time can be designed to mimic a desired plasma profile. Because the plasma profile produced by the modified release composition upon 10 administration is substantially similar to the plasma profile produced by the administration of two or more IR dosage forms given sequentially, the modified release composition of the present invention is particularly useful for administering ziprasidone. According to another aspect of the present invention, the composition can be 15 designed to produce a plasma profile that minimizes or eliminates the variations in plasma concentration levels associated with the administration of two or more IR dosage forms given sequentially. In such embodiments, the composition may be provided with an immediate release component to hasten the onset of action by minimizing the time from administration to a therapeutically effective plasma concentration level, and at least 20 one modified release component to maintain a therapeutically effective plasma concentration level throughout the dosing interval. The active ingredients in each component may be the same or different. For example, the composition may comprise components comprising only ziprasidone, or 25 nanoparticles containing the ziprasidone, as the active ingredient. Alternatively, the composition may comprise a first component comprising ziprasidone, or nanoparticles containing ziprasidone, and at least one subsequent component comprising an active ingredient other than the ziprasidone, or nanoparticles containing ziprasidone, suitable for co-administration with ziprasidone, or a first component containing an active ingredient 30 other than ziprasidone, or nanoparticles containing ziprasidone, and at least one subsequent component comprising ziprasidone, or nanoparticles containing ziprasidone. - 35 - WO 2007/027273 PCT/US2006/023695 Indeed, two or more active ingredients may be incorporated into the same component when the active ingredients are compatible with each other. An active ingredient present in one component of the composition may be accompanied by, for example, an enhancer compound or a sensitizer compound in another component of the composition, in order to 5 modify the bioavailability or therapeutic effect thereof. As used herein, the term "enhancer" refers to a compound which is capable of enhancing the absorption and/or bioavailability of an active ingredient by promoting net transport across the GIT in an animal, such as a human. Enhancers include but are not 10 limited to medium chain fatty acids; salts, esters, ethers and derivatives thereof, including glycerides and triglycerides; non-ionic surfactants such as those that can be prepared by reacting ethylene oxide with a fatty acid, a fatty alcohol, an alkylphenol or a sorbitan or glycerol fatty acid ester; cytochrome P450 inhibitors, P-glycoprotein inhibitors and the like; and mixtures of two or more of these agents. 15 In those embodiments in which more than one drug-containing component is present, the proportion of ziprasidone contained in each component may be the same or different depending on the desired dosing regime. The ziprasidone present in the first component and in subsequent components may be any amount sufficient to produce a 20 therapeutically effective plasma concentration level. The ziprasidone, when applicable, may be present either in the form of one substantially optically pure stereoisomer or as a mixture, racemic or otherwise, of two or more stereoisomers. In one embodiment, the ziprasidone is present in the composition in an amount of from about 0.1 to about 500 mg. In another embodiment, the ziprasidone is present in the composition in an amount of 25 from about 1 to about 100 mg. In yet another embodiment, the ziprasidone is present in the first component in an amount of from about 0.5 to about 60 mg. In still another embodiment, the ziprasidone is present in the first component in an amount of from about 2.5 to about 30 mg. If in subsequent components, the ziprasidone is present in amounts within similar ranges to those described for the first component. 30 - 36 - WO 2007/027273 PCT/US2006/023695 The time release characteristics for the delivery of ziprasidone from each of the components may be varied by modifying the composition of each component, including modifying any of the excipients and/or coatings which may be present. In particular, the release of ziprasidone may be controlled by changing the composition and/or the amount 5 of the modified release coating on the particles, if such a coating is present. If more than one modified release component is present, the modified release coating for each of these components may be the same or different. Similarly, when modified release is facilitated by the inclusion of a modified release matrix material, release of the active ingredient may be controlled by the choice and amount of modified release matrix material utilized. 10 The modified release coating may be present, in each component, in any amount that is sufficient to yield the desired delay time for each particular component. The modified release coating may be preset, in each component, in any amount that is sufficient to yield the desired time lag between components. 15 The lag time and/or time delay for the release of ziprasidone from each component may also be varied by modifying the composition of each of the components, including modifying any excipients and coatings which may be present. For example, the first component may be an immediate release component wherein ziprasidone is released immediately upon administration. Alternatively, the first component may be, for example, 20 a time-delayed immediate release component in which ziprasidone is released substantially in its entirety immediately after a time delay. The second and subsequent component may be, for example, a time-delayed immediate release component as just described or, alternatively, a time-delayed sustained release or extended release component in which ziprasidone is released in a controlled fashion over an extended 25 period of time. As will be appreciated by those skilled in the art, the exact nature of the plasma concentration curve will be influenced by the combination of all of these factors just described. In particular, the lag time between the delivery (and thus also the onset of 30 action) of ziprasidone in each component containing ziprasidone may be controlled by varying the composition and coating (if present) of each of the components. Thus by - 37 - WO 2007/027273 PCT/US2006/023695 variation of the composition of each component (including the amount and nature of the active ingredient(s)) and by variation of the lag time, numerous release and plasma profiles may be obtained. Depending on the duration of the lag time between the release of ziprasidone from each component and the nature of the release of ziprasidone from 5 each component (i.e. immediate release, sustained release etc.), the plasma profile may be continuous (i.e., having a single maximum) or pulsatile in which the peaks in the plasma profile may be well separated and clearly defined (e.g. when the lag time is long) or superimposed to a degree (e.g. when the lag time is short). 10 The plasma profile produced from the administration of a single dosage unit comprising the composition of the present invention is advantageous when it is desirable to deliver two or more pulses of active ingredient without the need for administration of two or more dosage units. 15 Any coating material which modifies the release of ziprasidone in the desired manner may be used. In particular, coating materials suitable for use in the practice of the present invention include but are not limited to polymer coating materials, such as cellulose acetate phthalate, cellulose acetate trimaletate, hydroxy propyl methylcellulose phthalate, polyvinyl acetate phthalate, ammonio methacrylate copolymers such as those 20 sold under the trademark Eudragit* RS and RL, poly acrylic acid and poly acrylate and methacrylate copolymers such as those sold under the trademark Eudragit® S and L, polyvinyl acetaldiethylamino acetate, hydroxypropyl methylcellulose acetate succinate, shellac; hydrogels and gel-forming materials, such as carboxyvinyl polymers, sodium alginate, sodium carmellose, calcium carmellose, sodium carboxymethyl starch, polyvinyl 25 alcohol, hydroxyethyl cellulose, methyl cellulose, gelatin, starch, and cellulose based cross-linked polymers--in which the degree of crosslinking is low so as to facilitate adsorption of water and expansion of the polymer matrix, hydoxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, crosslinked starch, microcrystalline cellulose, chitin, aminoacryl-methacrylate copolymer (Eudragit* RS 30 PM, Rohin & Haas), pullulan, collagen, casein, agar, gum arabic, sodium carboxymethyl cellulose, (swellable hydrophilic polymers) poly(hydroxyalkyl methacrylate) (mol. wt. -38- WO 2007/027273 PCT/US2006/023695 -5k-5,000k), polyvinylpyrrolidone (mol. wt. -10k-360k), anionic and cationic hydrogels, polyvinyl alcohol having a low acetate residual, a swellable mixture of agar and carboxymethyl cellulose, copolymers of maleic anhydride and styrene, ethylene, propylene or isobutylene, pectin (mol. wt. -30k-300k), polysaccharides such as agar, 5 acacia, karaya, tragacanth, algins and guar, polyacrylamides, Polyox* polyethylene oxides (mol. wt. - OOk-5,000k), AquaKeep* acrylate polymers, diesters of polyglucan, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone, sodium starch glucolate (e.g. Explotab*; Edward Mandell C. Ltd.); hydrophilic polymers such as polysaccharides, methyl cellulose, sodium or calcium carboxymethyl cellulose, hydroxypropyl methyl 10 cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, nitro cellulose, carboxymethyl cellulose, cellulose ethers, polyethylene oxides (e.g. Polyox*, Union Carbide), methyl ethyl cellulose, ethylhydroxy ethylcellulose, cellulose acetate, cellulose butyrate, cellulose propionate, gelatin, collagen, starch, maltodextrin, pullulan, polyvinyl pyrrolidone, polyvinyl alcohol, polyvinyl acetate, glycerol fatty acid esters, 15 polyacrylamide, polyacrylic acid, copolymers of methacrylic acid or methacrylic acid (e.g. Eudragit®, Rohm and Haas), other acrylic acid derivatives, sorbitan esters, natural gums, lecithins, pectin, alginates, ammonia alginate, sodium, calcium, potassium alginates, propylene glycol alginate, agar, and gums such as arabic, karaya, locust bean, tragacanth, carrageens, guar, xanthan, scleroglucan and mixtures and blends thereof. As 20 will be appreciated by the person skilled in the art, excipients such as plasticisers, lubricants, solvents and the like may be added to the coating. Suitable plasticisers include for example acetylated monoglycerides; butyl phthalyl butyl glycolate; dibutyl tartrate; diethyl phthalate; dimethyl phthalate; ethyl phthalyl ethyl glycolate; glycerin; propylene glycol; triacetin; citrate; tripropioin; diacetin; dibutyl phthalate; acetyl monoglyceride; 25 polyethylene glycols; castor oil; triethyl citrate; polyhydric alcohols, glycerol, acetate esters, gylcerol triacetate, acetyl triethyl citrate, dibenzyl plithalate, dihexyl plithalate, butyl octyl phthalate, diisononyl phthalate, butyl octyl phthalate, dioctyl azelate, epoxidised tallate, triisoctyl trimellitate, diethylhexyl phthalate, di-n-octyl phthalate, di-i octyl phthalate, di-i-decyl phthalate, di-n-undecyl phthalate, di-n-tridecyl phthalate, tri-2 30 ethylhexyl trimellitate, di-2-ethylhexyl adipate, di-2-ethylhexyl sebacate, di-2-ethylhexyl azelate, dibutyl sebacate. - 39 - WO 2007/027273 PCT/US2006/023695 When the modified release component comprises a modified release matrix material, any suitable modified release matrix material or suitable combination of modified release matrix materials may be used. Such materials are known to those skilled 5 in the art. The term "modified release matrix material" as used herein includes hydrophilic polymers, hydrophobic polymers and mixtures thereof which are capable of modifying the release of ziprasidone, or a salt or derivative thereof, dispersed therein in vitro or in vivo. Modified release matrix materials suitable for the practice of the present invention include but are not limited to microcrystalline cellulose, sodium 10 carboxymethylcellulose, hydoxyalkylcelluloses such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyethylene oxide, alkylcelluloses such as methylcellulose and ethylcellulose, polyethylene glycol, polyvinylpyrrolidone, cellulose acteate, cellulose acetate butyrate, cellulose acteate phthalate, cellulose acteate trimellitate, polyvinylacetate phthalate, polyalkylmethacrylates, polyvinyl acetate and mixture thereof. 15 A modified release composition according to the present invention may be incorporated into any suitable dosage form which facilitates release of the active ingredient in a pulsatile manner. In one embodiment, the dosage form comprises a blend of different populations of active ingredient-containing particles which make up the 20 immediate release and the modified release components, the blend being filled into suitable capsules, such as hard or soft gelatin capsules. Alternatively, the different individual populations of active ingredient-containing particles may be compressed (optionally with additional excipients) into mini-tablets which may be subsequently filled into capsules in the appropriate proportions. Another suitable dosage form is that of a 25 multilayer tablet. In this instance the first component of the modified release composition may be compressed into one layer, with the second component being subsequently added as a second layer of the multilayer tablet. The populations of the particles making up the composition of the invention may further be included in rapidly dissolving dosage forms such as an effervescent dosage form or a fast-melt dosage form. 30 - 40 - WO 2007/027273 PCT/US2006/023695 In one embodiment, the composition comprises at least two components containing ziprasidone: a first component and one or more subsequent components. In such embodiment, the first component of the composition may exhibit a variety of release profiles including profiles in which substantially all of the ziprasidone contained in the 5 first component is released rapidly upon administration of the dosage form, released rapidly but after a time delay (delayed release), or released slowly over time. In one such embodiment, the ziprasidone contained in the first component is released rapidly upon administration to a patient. As used herein, "released rapidly" includes release profiles in which at least about 80% of the active ingredient of a component is released within about 10 an hour after administration, the term "delayed release" includes release profiles in which the active ingredient of a component is released (rapidly or slowly) after a time delay, and the terms "controlled release" and "extended release" include release profiles in which at least about 80% of the active ingredient contained in a component is released slowly. 15 The second component of such embodiment may also exhibit a variety of release profiles including an immediate release profile, a delayed release profile or a controlled release profile. In one such embodiment, the second component exhibits a delayed release profile in which ziprasidone is released after a time delay. 20 The plasma profile produced by the administration of dosage forms of the present invention which comprise an immediate release component comprising ziprasidone, or nanoparticles containing ziprasidone, and at least one modified release component comprising ziprasidone, or nanoparticles containing ziprasidone, can be substantially similar to the plasma profile produced by the administration of two or more IR dosage 25 forms given sequentially, or to the plasma profile produced by the administration of separate IR and modified release dosage forms. Accordingly, the dosage forms of the present invention can be particularly useful for administering ziprasidone where the maintenance of pharmacokinetic parameters may be desired but is problematic. 30 In one embodiment, the composition and the solid oral dosage forms containing the composition release ziprasidone such that substantially all of the ziprasidone -41- WO 2007/027273 PCT/US2006/023695 contained in the first component is released prior to release of ziprasidone from the at least one subsequent component. When the first component comprises an IR component, for example, it is preferable that release of the ziprasidone from the at least one subsequent component is delayed until substantially all ziprasidone in the IR component 5 has been released. Release of ziprasidone from the at least one subsequent component may be delayed as detailed above by the use of a modified release coatings and/or a modified release matrix material. When it is desirable to minimize patient tolerance by providing a dosage regime 10 which facilitates wash-out of a first dose of ziprasidone from a patient's system, release of ziprasidone from subsequent components may be delayed until substantially all of the ziprasidone contained in the first component has been released, and further delayed until at least a portion of the ziprasidone released from the first component has been cleared from the patient's system. In one embodiment, release of the ziprasidone from subsequent 15 components of the composition is substantially, if not completely, delayed for a period of at least about two hours after administration of the composition. In another embodiment, the release of ziprasidone from subsequent components of the composition is substantially, if not completely, delayed for a period of at least about four hours after administration of the composition. 20 As described hereinbelow, the present invention also includes various types of modified release systems by which ziprasidone may be delivered in either a pulsatile or continuous manner. These systems include but are not limited to: films with ziprasidone, or nanoparticles containing ziprasidone, in a polymer matrix (monolithic devices); 25 systems in which ziprasidone, or nanoparticles containing ziprasidone, is contained by a polymer (reservoir devices); polymeric colloidal particles or microencapsulates (microparticles, microspheres or nanoparticles) in the form of reservoir and matrix devices; systems in which ziprasidone, or nanoparticles containing ziprasidone, is contained by a polymer which contains a hydrophilic and/or leachable additive e.g., a 30 second polymer, surfactant or plasticizer, etc. to give a porous device, or a device in which ziprasidone release may be osmotically controlled (both reservoir and matrix - 42 - WO 2007/027273 PCT/US2006/023695 devices); enteric coatings (ionizable and dissolve at a suitable pH); (soluble) polymers with (covalently) attached pendent ziprasidone molecules and devices where release rate is controlled dynamically: e.g., the osmotic pump. 5 The delivery mechanism of the present invention can control the rate of release of ziprasidone. While some mechanisms will release ziprasidone at a constant rate, others will vary as a function of time depending on factors such as changing concentration gradients or additive leaching leading to porosity, etc. 10 Polymers used in sustained release coatings are necessarily biocompatible, and ideally biodegradable. Examples of both naturally occurring polymers such as Aquacoat* (FMC Corporation, Food & Pharmaceutical Products Division, Philadelphia, USA) (ethylcellulose mechanically spheronised to sub-micron sized, aqueous based, pseudo-latex dispersions), and also synthetic polymers such as the Eudragit*' (Rbhm 15 Pharma, Weiterstadt.) range of poly(acrylate, methacrylate) copolymers are known in the art. Reservoir Devices A typical approach to modified release is to encapsulate or contain the drug 20 entirely (e.g., as a core), within a polymer film or coat (i.e., microcapsules or spray/pan coated cores). The various factors that can affect the diffusion process may readily be applied to reservoir devices (e.g., the effects of additives, polymer functionality (and, hence, sink 25 solution pH) porosity, film casting conditions, etc.) and, hence, the choice of polymer must be an important consideration in the development of reservoir devices. Modeling the release characteristics of reservoir devices (and monolithic devices) in which the transport of ziprasidone is by a solution-diffusion mechanism therefore typically involves a solution to Fick's second law (unsteady-state conditions; concentration dependent flux) 30 for the relevant boundary conditions. When the device contains dissolved active agent, the rate of release decreases exponentially with time as the concentration (activity) of the - 43 - WO 2007/027273 PCT/US2006/023695 agent (i.e., the driving force for release) within the device decreases (i.e., first order release). If, however, the active agent is in a saturated suspension, then the driving force for release is kept constant until the device is no longer saturated. Alternatively the release-rate kinetics may be desorption controlled, and a function of the square root of 5 time. Transport properties of coated tablets, may be enhanced compared to free polymer films, due to the enclosed nature of the tablet core (permeant) which may enable the internal build-up of an osmotic pressure which will then act to force the permeant out 10 of the tablet. The effect of de-ionized water on salt containing tablets coated in poly(ethylene glycol) (PEG)-containing silicone elastomer, and also the effects of water on free films has been investigated. The release of salt from the tablets was found to be a mixture of 15 diffusion through water filled pores, formed by hydration of the coating, and osmotic pumping. KCl transport through films containing just 10% PEG was negligible, despite extensive swelling observed in similar free films, indicating that porosity was necessary for the release of the KC1 which then occurred by trans-pore diffusion. Coated salt tablets, shaped as disks, were found to swell in de-ionized water and change shape to an 20 oblate spheroid as a result of the build-up of internal hydrostatic pressure: the change in shape providing a means to measure the force generated. As might be expected, the osmotic force decreased with increasing levels of PEG content. The lower PEG levels allowed water to be imbibed through the hydrated polymer, while the porosity resulting from the coating dissolving at higher levels of PEG content (20 to 40%) allow the 25 pressure to be relieved by the flow of KCI. Methods and equations have been developed, which by monitoring (independently) the release of two different salts (e.g., KCI and NaCl) allowed the calculation of the relative magnitudes that both osmotic pumping and trans-pore diffusion 30 contributed to the release of salt from the tablet. At low PEG levels, osmotic flow was increased to a greater extent than was trans-pore diffusion due to the generation of only a - 44 - WO 2007/027273 PCT/US2006/023695 low pore number density: at a loading of 20%, both mechanisms contributed approximately equally to the release. The build-up of hydrostatic pressure, however, decreased the osmotic inflow, and osmotic pumping. At higher loadings of PEG, the hydrated film was more porous and less resistant to outflow of salt. Hence, although the 5 osmotic pumping increased (compared to the lower loading), trans-pore diffusion was the dominant release mechanism. An osmotic release mechanism has also been reported for microcapsules containing a water soluble core. Monolithic Devices (Matrix Devices) 10 Monolithic (matrix) devices may be used for controlling the release of a drug. This is possibly because they are relatively easy to fabricate compared to reservoir devices, and the danger of an accidental high dosage that could result from the rupture of the membrane of a reservoir device is not present. In such a device, the active agent is present as a dispersion within the polymer matrix, and they are typically formed by the 15 compression of a polymer/drug mixture or by dissolution or melting. The dosage release properties of monolithic devices may be dependent upon the solubility of the drug in the polymer matrix or, in the case of porous matrixes, the solubility in the sink solution within the particle's pore network, and also the tortuosity of the network (to a greater extent than the permeability of the film), dependent on whether the drug is dispersed in 20 the polymer or dissolved in the polymer. For low loadings of drug (0 to 5% W/V), the drug will be released by a solution-diffusion mechanism (in the absence of pores). At higher loadings (5 to 10% W/V), the release mechanism will be complicated by the presence of cavities formed near the surface of the device as the drug is lost: such cavities fill with fluid from the environment increasing the rate of release of the drug. 25 It is common to add a plasticizer (e.g., a poly(ethylene glycol)), a surfactant, or adjuvant (i.e., an ingredient which increases effectiveness), to matrix devices (and reservoir devices) as a means to enhance the permeability (although, in contrast, plasticizers may be fugitive, and simply serve to aid film formation and, hence, decrease 30 permeability - a property normally more desirable in polymer paint coatings). It was noted that the leaching of PEG increased the permeability of (ethyl cellulose) films - 45 - WO 2007/027273 PCT/US2006/023695 linearly as a function of PEG loading by increasing the porosity, however, the films retained their barrier properties, not permitting the transport of electrolyte. It was deduced that the enhancement of their permeability was as a result of the effective decrease in thickness caused by the PEG leaching. This was evidenced from plots of the 5 cumulative permeant flux per unit area as a function of time and film reciprocal thickness at a PEG loading of 50% W/W: plots showing a linear relationship between the rate of permeation and reciprocal film thickness, as expected for a (Fickian) solution-diffusion type transport mechanism in a homogeneous membrane. Extrapolation of the linear regions of the graphs to the time axis gave positive intercepts on the time axis: the 10 magnitude of which decreased towards zero with decreasing film thickness. These changing lag times were attributed to the occurrence of two diffusional flows during the early stages of the experiment (the flow of the drug and also the flow of the PEG), and also to the more usual lag time during which the concentration of permeant in the film is building-up. Caffeine, when used as a permeant, showed negative lag times. No 15 explanation of this was forthcoming, but it was noted that caffeine exhibited a low partition coefficient in the system, and that this was also a feature of aniline permeation through polyethylene films which showed a similar negative time lag. The effects of added surfactants on (hydrophobic) matrix devices has been 20 investigated. It was thought that surfactant may increase the release rate of a drug by three possible mechanisms: (i) increased solubilization, (ii) improved 'wettability' to the dissolution media, and (iii) pore formation as a result of surfactant leaching. For the system studied (Eudragite RL 100 and RS 100 plasticized by sorbitol, flurbiprofen as the drug, and a range of surfactants) it was concluded that improved wetting of the tablet led 25 to only a partial improvement in drug release (implying that the release was diffusion, rather than dissolution, controlled), although the effect was greater for Eudragit* RS than Eudragit* RL, while the greatest influence on release was by those surfactants that were more soluble due to the formation of disruptions in the matrix allowing the dissolution medium access to within the matrix. This is of obvious relevance to a study of latex films 30 which might be suitable for pharmaceutical coatings, due to the ease with which a polymer latex may be prepared with surfactant as opposed to surfactant-free. Differences - 46 - WO 2007/027273 PCT/US2006/023695 were found between the two polymers with only the Eudragit* RS showing interactions between the anionic/cationic surfactant and drug. This was ascribed to the differing levels of quaternary ammonium ions on the polymer. 5 Composite devices consisting of a polymer/drug matrix coated in a polymer containing no drug also exist. Such a device was constructed from aqueous Eudragit* lattices, and was found to provide a continuous release by diffusion of the drug from the core through the shell. Similarly, a polymer core containing the drug has been produced and coated with a shell that was eroded by gastric fluid. The rate of release of the drug 10 was found to be relatively linear (a function of the rate limiting diffusion process through the shell) and inversely proportional to the shell thickness, whereas the release from the core alone was found to decrease with time. Microspheres 15 Methods for the preparation of hollow microspheres have been described. Hollow microspheres were formed by preparing a solution of ethanol/dichloromethane containing the drug and polymer. On pouring into water, an emulsion is formed containing the dispersed polymer/drug/solvent particles, by a coacervation-type process from which the ethanol rapidly diffused precipitating polymer at the surface of the 20 droplet to give a hard-shelled particle enclosing the drug dissolved in the dichloromethane. A gas phase of dichloromethane was then generated within the particle which, after diffusing through the shell, was observed to bubble to the surface of the aqueous phase. The hollow sphere, at reduced pressure, then filled with water which could be removed by a period of drying. No drug was found in the water. Highly porous 25 matrix-type microspheres have also been described. The matrix-type microspheres were prepared by dissolving the drug and polymer in ethanol. On addition to water, the ethanol diffused from the emulsion droplets to leave a highly porous particle. A suggested use of the microspheres was as floating drug delivery devices for use in the stomach. 30 -47 - WO 2007/027273 PCT/US2006/023695 Pendent devices A means of attaching a range of drugs such as analgesics and antidepressants, etc., by means of an ester linkage to poly(acrylate) ester latex particles prepared by aqueous emulsion polymerization has been developed. These lattices, when passed 5 through an ion exchange resin such that the polymer end groups were converted to their strong acid form, could self-catalyze the release of the drug by hydrolysis of the ester link. Drugs have been attached to polymers, and also monomers have been synthesized 10 with a pendent drug attached. Dosage forms have been prepared in which the drug is bound to a biocompatible polymer by a labile chemical bond e.g., polyanhydrides prepared from a substituted anhydride (itself prepared by reacting an acid chloride with the drug: methacryloyl chloride and the sodium salt of methoxy benzoic acid) were used to form a matrix with a second polymer (Eudragit* RL) which released the drug on 15 hydrolysis in gastric fluid. The use of polymeric Schiff bases suitable for use as carriers of phannaceutical amines has also been described. Enteric films Enteric coatings consist of pH sensitive polymers. Typically the polymers are 20 carboxylated and interact very little with water at low pH, while at high pH the polymers ionize causing swelling or dissolving of the polymer. Coatings can therefore be designed to remain intact in the acidic environment of the stomach, protecting either the drug from this environment or the stomach from the drug, but to dissolve in the more alkaline environment of the intestine. 25 Osmotically controlled devices The osmotic pump is similar to a reservoir device but contains an osmotic agent (e.g., the active agent in salt form) which acts to imbibe water from the surrounding medium via a semi-permeable membrane. Such a device, called an elementary osmotic 30 pump, has been described. Pressure is generated within the device which forces the active agent out of the device via an orifice of a size designed to minimize solute diffusion, - 48 - WO 2007/027273 PCT/US2006/023695 while preventing the build-up of a hydrostatic pressure head which can have the effect of decreasing the osmotic pressure and changing the dimensions of the device. While the internal volume of the device remains constant, and there is an excess of solid or saturated solution in the device, then the release rate remains constant delivering a 5 volume equal to the volume of solvent uptake. Electrically stimulated release devices Monolithic devices have been prepared using polyelectrolyte gels which swell when, for example, an external electrical stimulus is applied causing a change in pH. The 10 release may be modulated by changes in the applied current to produce a constant or pulsatile release profile. Hydrogels In addition to their use in drug matrices, hydrogels find use in a number of 15 biomedical applications such as, for example, soft contact lenses, and various soft implants, and the like. I1. Methods of Using Modified Release Compositions Comprising Ziprasidone According to another aspect of the present invention, there is provided a method 20 for treating a patient suffering from schizophrenia or a similar psychiatric disorder comprising the step of administering a therapeutically effective amount of the composition of the present invention in solid oral dosage form. Advantages of the method of the present invention include a reduction in the dosing frequency required by conventional multiple IR dosage regimes while still maintaining the benefits derived 25 from a pulsatile plasma profile or eliminating or minimizing the variations in plasma concentration levels. This reduced dosing frequency is advantageous in terms of patient compliance and the reduction in dosage frequency made possible by the method of the present invention would contribute to controlling health care costs by reducing the amount of time spent by health care workers on the administration of ziprasidone. 30 - 49 - WO 2007/027273 PCT/US2006/023695 In the following examples, all percentages are weight by weight unless otherwise stated. The term "purified water" as used throughout the Examples refers to water that has been purified by passing it through a water filtration system. It is to be understood that the examples are for illustrative purposes only, and should not be interpreted as restricting the 5 spirit and breadth of the invention as defined by the scope of the claims that follow. Examples Examples 1 to 4 provide exemplary ziprasidone tablet formulations. These examples are not intended to limit the claims in any respect, but rather to provide 10 exemplary tablet formulations of ziprasidone which can be utilized in the methods of the invention. Such exemplary tablets can also comprise a coating agent. Example I Exemplary Nanoparticulate Ziprasidone Tablet Formulation #1 Component g/Kg Ziprasidone about 50 to about 500 Hypromellose, USP about 10 to about 70 Docusate Sodium, USP about 1 to about 10 Sucrose, NF about 100 to about 500 Sodium Lauryl Sulfate, NF about 1 to about 40 Lactose Monohydrate, NF about 50 to about 400 Silicified Microcrystalline Cellulose about 50 to about 300 Crospovidone, NF about 20 to about 300 Magnesium Stearate, NF about 0.5 to about 5 15 - 50 - WO 2007/027273 PCT/US2006/023695 Example 2 Exemplary Nanoparticulate Ziprasidone Tablet Formulation #2 Component g/Kg Ziprasidone about 100 to about 300 Hypromellose, USP about 30 to about 50 Docusate Sodium, USP about 0.5 to about 10 Sucrose, NF about 100 to about 300 Sodium Lauryl Sulfate, NF about 1 to about 30 Lactose Monohydrate, NF about 100 to about 300 Silicified Microcrystalline Cellulose about 50 to about 200 Crospovidone, NF about 50 to about 200 Magnesium Stearate, NF about 0.5 to about 5 5 Example 3 Exemplary Nanoparticulate Ziprasidone Tablet Formulation #3 Component g/Kg Ziprasidone about 200 to about 225 Hypromellose, USP about 42 to about 46 Docusate Sodium, USP about 2 to about 6 Sucrose, NF about 200 to about 225 Sodium Lauryl Sulfate, NF about 12 to about 18 Lactose Monohydrate, NF about 200 to about 205 Silicified Microcrystalline Cellulose about 130 to about 135 Crospovidone, NF about 112 to about 118 Magnesium Stearate, NF about 0.5 to about 3 Example 4 Exemplary Nanoparticulate Ziprasidone Tablet Formulation #4 Component g/Kg Ziprasidone about 119 to about 224 Hypromellose, USP about 42 to about 46 Docusate Sodium, USP about 2 to about 6 Sucrose, NF about 119 to about 224 Sodium Lauryl Sulfate, NF about 12 to about 18 Lactose Monohydrate, NF about 119 to about 224 Silicified Microcrystalline Cellulose about 129 to about 134 Crospovidone, NF about 112 to about 118 Magnesium Stearate, NF about 0.5 to about 3 - 51- WO 2007/027273 PCT/US2006/023695 Example 5 Multiparticulate Modified-release Composition Containing Ziprasidone A multiparticulate modified-release composition according to the present 5 invention comprising an immediate release component and a modified-release component containing ziprasidone is prepared as follows. (a) Immediate Release (IR) Component. A solution of ziprasidone is prepared according to any of the formulations given 10 in Table 1. The methylphenidate solution is then coated onto nonpareil seeds to a level of approximately 16.9% solids weight gain using, for example, a Glatt GPCG3 (Glatt, Protech Ltd., Leicester, UK) fluid bed coating apparatus to form the IR particles of the immediate release component. 15 TABLE 1 Immediate release component solutions Amount, % (w/w) Ingredient (i) (ii) 20 Ziprasidone 13.0 13.0 Polyethylene Glycol 6000 0.5 0.5 Polyvinylpyrrolidone 3.5 Purified Water 83.5 86.5 25 (b) Modified-release Component Ziprasidone-containing delayed release particles are prepared by coating immediate release particles prepared according to Example 5(a) above with a modified 30 release coating solution as detailed in Table 2. The immediate release particles are coated to varying levels up to approximately to 30% weight gain using, for example, a fluid bed apparatus. - 52 - WO 2007/027273 PCT/US2006/023695 TABLE 2 Modified release component coating solutions Amount, % (w/w) Ingredient (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) 5 Eudragit* 49.7 42.0 47.1 53.2 40.6 - - 25.0 RS 12.5 Eudragit* - - - - - 54.35 46.5 S 12.5 Eudragit* - - -- - - - 25.0 10 L 12.5 Polyvinyl- -- - - 0.35 0.3 - - pyrrolidone Diethyl- 0.5 0.5 0.6 1.35 0.6 1.3 1.1 plithalate 15 Triethyl- -- - - - - - - 1.25 citrate Isopropyl 39.8 33.1 37.2 45.1 33.8 44.35 49.6 46.5 alcohol Acetone 10.0 8.3 9.3 - 8.4 -- - 20 Talcl - 16.0 5.9 - 16.3 -- 2.8 2.25 Tale is simultaneously applied during coating for formulations in column (i), (iv) and (vi). (c) Encapsulation of Immediate and Delayed Release Particles. 25 The immediate and delayed release particles prepared according to Example 5(a) and (b) above are encapsulated in size 2 hard gelatin capsules to an overall 20 mg dosage strength using, for example, a Bosch GKF 4000S encapsulation apparatus. The overall dosage strength of 20 mg ziprasidone was made up of 10 mg from the immediate release 30 component and 10 mg from the modified-release component. EXAMPLE 6 Multiparticulate Modified-release Composition Containing Ziprasidone 35 Multiparticulate modified-release ziprasidone compositions according to the present invention having an immediate release component and a modified-release component having a modified-release matrix material are prepared according to the formulations shown in Table 3(a) and (b). 40 - 53 - WO 2007/027273 PCT/US2006/023695 TABLE 3 (a) 100 mg of IR component is encapsulated with 100 mg of modified release (MR) component to give a 20 mg dosage strength product % (w/w) 5 IR component Ziprasidone 10 Microcrytalline cellulose 40 Lactose 45 10 Povidone 5 MR component Ziprasidone 10 15 Microcrytalline cellulose 40 Eudragit* RS 45 Povidone 5 TABLE 3 (b) 20 50 mg of IR component is encapsulated with 50 mg of modified release (MR) component to give a 20 mg dosage strength product. % (w/w) IR component 25 Ziprasidone 20 Microcrystalline cellulose 50 Lactose 28 Povidone 2 30 MR component Ziprasidone 20 Microcrytalline cellulose 50 Eudragit* S 28 35 Povidone 2 EXAMPLE 7 The purpose of this example is describe how a nanoparticulate ziprasidone composition may be prepared. 40 An aqueous dispersion of 5% (w/w) ziprasidone, combined with one or more surface stabilizers, such as hydroxypropyl cellulose (HPC-SL) and dioctylsulfosuccinate (DOSS), may be milled in a 10 ml chamber of a NanoMill* 0.01 (NanoMill Systems, - 54 - WO 2007/027273 PCT/US2006/023695 King of Prussia, PA; see e.g., U.S. Patent No. 6,431,478), along with 500 micron PolyMill* attrition media (Dow Chemical Co.) (e.g., at an 89% media load). In an exemplary process, the mixture may be milled at a speed of 2500 rpms for 60 minutes. 5 Following milling, the particle size of the milled ziprasidone particles can be measured, in deionized distilled water, using a Horiba LA 910 particle size analyzer. For a successful composition, the initial mean and/or D50 milled ziprasidone particle size is expected to be less than 2000 nm. 10 It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present inventions without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modification and variations of the invention provided they come within the scope of the appended claims and their equivalents. 15 - 55 -

Claims (91)

1. A stable nanoparticulate composition comprising: (A) particles comprising ziprasidone, said particles having an effective average particle size of less than about 2000 rm in diameter; and (B) at least one surface stabilizer.

2. The composition of claim 1, wherein said particles are in a crystalline phase, an amorphous phase, a semi-crystalline phase, a semi amorphous phase, or a mixture thereof.

3. The composition of claim 1, wherein the effective average particle size of said particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nim, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 im, less than about 1200 nim, less than about 1100 nm, less than about 1000 nm, less than about 900 im, less than about 800 nm, less than about 700 rim, less than about 600 nim, less than about 500 nim, less than about 400 nm, less than about 300 nim, less than about 250 nm, less than about 200 nim, less than about 100 nm, less than about 75 nm, and less than about 50 nim in diameter.

4. The composition of claim 1, wherein the composition is formulated: (A) for administration selected from the group consisting of parenterally, orally, vaginally, nasally, rectally, otically, ocularly, locally, buccally, intracisternally, intraperitoneally, or topically; (B) into a dosage form selected from the group consisting of tablets, capsules, sachets, solutions, dispersions, gels, aerosols, ointments, creams, and mixtures thereof; (C) into a formulation selected from the group consisting of controlled release formulations, fast melt formulations, lyophilized formulations, delayed release formulations, extended release formulations, pulsatile release formulations, and mixed immediate release and controlled release fonnulations; or 56 WO 2007/027273 PCT/US2006/023695 (D) any combination of (A), (B), or (C).

5. The composition of claim 1 further comprising one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

6. The composition of claim 1, wherein: (A) said ziprasidone is present in said composition in an amount selected from the group consisting of from about 99.5% to about 0.00 1%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight of the total combined dry weight of ziprasidone and surface stabilizer in the composition, not including other excipients; (B) said surface stabilizer or surface stabilizers are present in a total amount of from about 0.5% to about 99.999%, from about 5.0% to about 99.9%, or from about 10% to about 99.5% by weight, based on the total combined dry weight of ziprasidone and surface stabilizer in the composition not including other excipients; or (C) a combination of (A) and (B).

7. The composition of claim 1, wherein the surface stabilizer is selected from the group consisting of a non-ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, a zwitterionic surface stabilizer, and an ionic surface stabilizer.

8. The composition of claim 1, wherein the surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, 57 WO 2007/027273 PCT/US2006/023695 hypromellose plithalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4-(1,1,3,3-tetramethylbutyl) phenol polymer with ethylene oxide and formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N-methylglucamide; n decyl P-D-glucopyranoside; n-decyl P-D-maltopyranoside; n-dodecyl P-D glucopyranoside; n-dodecyl p-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-p-D glucopyranoside; n-heptyl f-D-thioglucoside; n-hexyl P-D-glucopyranoside; nonanoyl-N methylglucamide; n-noyl P-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-p D-glucopyranoside; octyl P-D-thioglucopyranoside; lysozyme, PEG-phospholipid, PEG cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl acetate and vinyl pyrrolidone, a cationic polymer, a cationic biopolymer, a cationic polysaccharide, a cationic cellulosic, a cationic alginate, a cationic nonpolymeric compound, a cationic phospholipid, cationic lipids, polymethylmethacrylate trimethylammonium bromide, sulfonium compounds, polyvinylpyrrolidone-2 dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, phosphonium compounds, quartemary ammonium compounds, benzyl-di(2 chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammonium chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C 1 2 - 1 5 dimethyl hydroxyethyl ammonium chloride, C 1 2 i 5 dimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammonium bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride, lauryl dimethyl (ethenoxy) 4 ammonium bromide, N-alkyl (C 12 -18)dimethylbenzyl ammonium chloride, N-alkyl (C14.1s)dimethyl-benzyl ammonium chloride, N tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C 1 2-14) dimethyl 1-napthyhnethyl ammonium chloride, 58 WO 2007/027273 PCT/US2006/023695 trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C] 2 . 1 4 ) dimethyl 1-naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammonium chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammonium bromide, C 1 2 trimethyl ammonium bromides, C 1 5 trimethyl ammonium bromides, C 1 7 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, POLYQUAT 10 TM, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, MIRAPOLTM, ALKAQUAT TM , alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.

9. The composition of claim 1, wherein the composition does not produce significantly different absorption levels when administered under fed as compared to fasting conditions.

10. The composition of claim 1, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state.

11. The composition of claim 1, wherein the pharmacokinetic profile of the composition is not significantly affected by the fed or fasted state of a subject ingesting said composition. 59 WO 2007/027273 PCT/US2006/023695

12. A composition of claim I wherein, upon administration of said composition to a mammal, the composition produces therapeutic results at a dosage which is less than that of a non-nanoparticulate dosage form of ziprasidone.

13. A composition of claim I which has: (a) a Cmax for ziprasidone when assayed in the plasma of a mammalian subject following administration, that is greater than the Cmax for the same ziprasidone when administered at the same dose using a non-nanoparticulate formulation; (b) an AUC for ziprasidone when assayed in the plasma of a mammalian subject following administration, that is greater than the AUC for the same ziprasidone when administered at the same dose using a non-nanoparticulate formulation; (c) a Tmax for ziprasidone when assayed in the plasma of a mammalian subject following administration, that is less than the Tmax for the same ziprasidone when administered at the same dose using a non-nanoparticulate formulation; or (d) any combination of (a), (b), and (c).

14. The composition of claim 1, additionally comprising one or more active compounds useful for the prevention and treatment of schizophrenia and similar psychiatric disorders

15. The composition of claim 14, wherein the one or more active compounds is selected from the group consisting of compounds useful in the treatment of a condition selected from the group consisting of headaches, soreness, fever, and combinations thereof.

16. The composition of claim 1 wherein said particles contain a reservoir which contains ziprasidone said reservoir being enclosed by a semi-permeable membrane which allows for water to be imbibed into said particles, thus generating pressure which forces said ziprasidone out of said particles.

17. The composition of claim 1 wherein said reservoir comprises also an osmotic agent. 60 WO 2007/027273 PCT/US2006/023695

18. A method of preparing the composition of claim I comprising contacting particles comprising said ziprasidone with at least one surface stabilizer for a period of time and under conditions sufficient to provide a nanoparticulate composition comprising ziprasidone having an effective average particle size of less than about 2000 nm in diameter.

19. The method of claim 18, wherein the contacting comprises grinding, wet grinding, homogenization, precipitation, template emulsion, or supercritical fluid particle generation techniques.

20. The method of claim 18, wherein the effective average particle size of the nanoparticulate particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1000 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 900 nm, less than about 800 nm, less than about 700 mu, less than about 600 nm, less than about 500 mu, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 mu, less than about 100 nm, less than about 75 nm, and less than about 50 nm in diameter.

21. A method of preventing and/or treating schizophrenia or a similar psychiatric disorders comprising administering a composition according to claim 1.

22. The method of claim 21, wherein the effective average particle size of the particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 mu, less than about 1600 nm, less than about 1500 nm, less than about 1000 nm, less than about 1400 nm, less than about 1300 mu, less than about 1200 nm, less than about 1100 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm in diameter. 61 WO 2007/027273 PCT/US2006/023695

23. A pharmaceutical composition comprising a first component of active ingredient containing particles and at least one subsequent component of active ingredient-containing particles, wherein at least one of said components comprises ziprasidone and at least one of said components further comprises a modified release coating, a modified release matrix material, or both, such that the composition, following oral delivery to a subject, delivers the active ingredient in a bimodal or multimodal manner.

24. The composition of claim 23 wherein each component comprises ziprasidone containing particles.

25. The composition of claim 23 wherein the composition comprises a first component of ziprasidone-containing particles and one subsequent component of ziprasidone containing particles.

26. The composition of claim 25, wherein the first component comprises an immediate release component and the second component comprises a modified release component.

27. The composition of claim 23, wherein the active ingredient-containing particles are erodable.

28. The composition of claim 23, wherein at least one of said components further comprises a modified-release coating.

29. The composition of claim 23, wherein at least one of said components further comprises a modified-release matrix material.

30. The composition of claim 29, wherein said modified release matrix material is selected from the group consisting of hydrophilic polymers, hydrophobic polymers, natural polymers, synthetic polymers and mixtures thereof 62 WO 2007/027273 PCT/US2006/023695

31. The composition of claim 30 wherein the ziprasidone is released to the surrounding environment by erosion.

32. The composition of claim 31 wherein said composition further comprises an enhancer.

33. The composition of claim 30 comprising from about 0.1 mg to about 1 g of ziprasidone.

34. A pharmaceutical composition comprising a first component of active ingredient containing particles and at least one subsequent component of active ingredient-containing particles, wherein at least one of said components comprises ziprasidone and at least one of said components further comprises a modified release coating, a modified release matrix material, or both, such that the composition, following oral delivery to a subject, delivers the active ingredient in a continuous manner.

35. The composition of claim 34 wherein each component comprises ziprasidone containing particles.

36. The composition of claim 34 wherein the composition comprises a first component of ziprasidone-containing particles and one subsequent component of ziprasidone containing particles.

37. The composition of claim 36, wherein the first component comprises an immediate release component and the second component comprises a modified release component.

38. The composition of claim 34, wherein the active ingredient-containing particles are erodable.

39. The composition of claim 34, wherein at least one of said components further comprises a modified-release coating. 63 WO 2007/027273 PCT/US2006/023695

40. The composition of claim 34, wherein at least one of said components further comprises a modified-release matrix material.

41. The composition of claim 40, wherein said modified release matrix material is selected from the group consisting of hydrophilic polymers, hydrophobic polymers, natural polymers, synthetic polymers and mixtures thereof

42. The composition of claim 41 wherein the ziprasidone is released to the surrounding environment by erosion.

43. The composition of claim 42 wherein said composition further comprises an enhancer.

44. The composition of claim 41 comprising from about 0.1 mg to about I g of ziprasidone.

45. A dosage form comprising the composition of claim 23.

46. The dosage form of claim 45 comprising a blend of active ingredient-containing particles contained within a hard gelatin or soft gelatin capsule.

47. The dosage form of claim 46, wherein the active ingredient-containing particles are in the form of mini-tablets and the capsule contains a mixture of said mini-tablets.

48. The dosage form of claim 47 in the form of tablet.

49. The dosage form of claim 48 wherein the ziprasidone-containing particles are provided in a rapidly dissolving dosage form.

50. The dosage form of claim 48 wherein the tablet is a fast-melt tablet. 64 WO 2007/027273 PCT/US2006/023695

51. A dosage form comprising the composition of claim 34.

52. The dosage form of claim 51 comprising a blend of active ingredient-containing particles contained within a hard gelatin or soft gelatin capsule.

53. The dosage form of claim 52, wherein the active ingredient-containing particles are in the form of mini-tablets and the capsule contains a mixture of said mini-tablets.

54. The dosage form of claim 53 in the form of tablet.

55. The dosage form of claim 54 wherein the ziprasidone-containing particles are provided in a rapidly dissolving dosage form.

56. The dosage form of claim 54 wherein the tablet is a fast-melt tablet.

57. A method for preventing and/or treating schizophrenia or a similar psychiatric disorders comprising the step of administering a therapeutically effective amount of the composition of claim 23.

58. A method for preventing and/or treating schizophrenia or a similar psychiatric disorders comprising the step of administering a therapeutically effective amount of the composition of claim 34.

59. The composition of claim 28 wherein the modified-release coating comprises a pH dependent polymer coating for releasing a pulse of the active ingredient in said patient following a time delay of about 6 to about 12 hours after administration of said composition to said patient.

60. The composition of claim 59, wherein said polymer coating comprises methacrylate copolymers. 65 WO 2007/027273 PCT/US2006/023695

61. The composition of claim 59, wherein the polymer coating comprises a mixture of methacrylate and ammoniomethacrylate copolymers in a ratio sufficient to achieve a pulse of the active ingredient following a time delay of at least about 6 hours.

62. The composition of claim 61, wherein the ratio of methacrylate to ammonio methacrylate copolymers is approximately 1:1.

63. The composition of claim 39 wherein the modified-release coating comprises a pH dependent polymer coating for releasing a pulse of the active ingredient in said patient following a time delay of about 6 to about 12 hours after administration of said composition to said patient.

64. The composition of claim 63, wherein said polymer coating comprises methacrylate copolymers.

65. The composition of claim 64, wherein the polymer coating comprises a mixture of methacrylate and ammoniomethacrylate copolymers in a ratio sufficient to achieve a pulse of the active ingredient following a time delay of at least about 6 hours.

66. The composition of claim 65, wherein the ratio of methacrylate to ammonio methacrylate copolymers is approximately 1:1.

67. A controlled release composition comprising a population of nanoparticulate particles which comprise: (A) ziprasidone; and (B) a modified release coating or, alternatively or additionally, a modified release matrix material; such that the composition following oral delivery to a subject delivers the ziprasidone in a pulsatile or continuous manner. 66 WO 2007/027273 PCT/US2006/023695

68. The composition of claim 67, wherein said composition does not produce significantly different absorption levels when administered under fed as compared to fasting conditions.

69. The composition of claim 67, wherein the pharmacokinetic profile of said composition is not significantly affected by the fed or fasted state of a subject ingesting said composition.

70. The composition of claim 67, wherein administration of said composition to a subject in a fasted state is bioequivalent to administration of said composition to a subject in a fed state.

71. The composition of claim 67, wherein the population comprises modified-release particles.

72. The composition of claim 67, wherein the population is an erodable formulation.

73. The composition of claim 67, wherein said particles are each in the form of an osmotic device.

74. The composition of claim 71, wherein the modified release particles comprise a modified-release coating.

75. The composition of claim 71, wherein the modified release particles comprise a modified-release matrix material.

76. The composition of claim 71 wherein said modified release particles are combined in a formulation that releases said ziprasidone by erosion to the surrounding environment.

77. The composition of claim 71, further comprising an enhancer. 67 WO 2007/027273 PCT/US2006/023695

78. The composition of claim 71, wherein the amount of active ingredient contained therein is from about 0.1 mg to about 1 g.

79. A dosage form comprising the composition of claim 67.

80. The dosage form of claim 79 comprising a blend of active ingredient-containing particles contained within a hard gelatin or soft gelatin capsule.

81. The dosage form of claim 80, wherein the active ingredient-containing particles are in the form of mini-tablets and the capsule contains a mixture of said mini-tablets.

82. The dosage form of claim 81 in the form of tablet.

83. The dosage form of claim 82 wherein the ziprasidone-containing particles are provided in a rapidly dissolving dosage form.

84. The dosage form of claim 82 wherein the tablet is a fast-melt tablet.

85. A method for the prevention and/or treatment of schizophrenia or a similar psychiatric disorder comprising administering a therapeutically effective amount of a composition of claim 67.

86. The composition of claim 71, wherein the modified-release particles comprise a pH-dependent polymer coating which is effective in releasing a pulse release of the active ingredient following a time delay of six to twelve hours.

87. The composition of claim 86, wherein the polymer coating comprises methacrylate copolymers. 68 WO 2007/027273 PCT/US2006/023695

88. The composition of claim 86, wherein the polymer coating comprises a mixture of methacrylate and ammonio methacrylate copolymers in a ratio sufficient to achieve a pulse release of the active ingredient following a time delay.

89. The composition of claim 88, wherein the ratio of methacrylate to ammonio methacrylate copolymers is approximately 1:1.

90. The composition of claim 67, wherein said particles are each in the form of an osmotic device.

91. The composition of claim 1, wherein the composition is formulated as a depot dosage form. 69